Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
19.68
-0.41 (-2.04%)
At close: Feb 26, 2026, 4:00 PM EST
23.70
+4.02 (20.43%)
After-hours: Feb 26, 2026, 7:05 PM EST
Neurogene Market Cap
Neurogene has a market cap or net worth of $304.84 million as of February 26, 2026. Its market cap has increased by 8.64% in one year.
Market Cap
304.84M
Enterprise Value
41.51M
1-Year Change
8.64%
Ranking
Category
Stock Price
$19.68
Market Cap Chart
Since December 19, 2023, Neurogene's market cap has increased from $193.64M to $304.84M, an increase of 57.43%. That is a compound annual growth rate of 23.04%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 25, 2026 | 311.19M | -2.48% |
| Dec 31, 2025 | 319.09M | -6.03% |
| Dec 31, 2024 | 339.58M | 36.64% |
| Dec 29, 2023 | 248.52M | 28.34% |
| Dec 19, 2023 | 193.64M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Sutro Biopharma | 334.97M |
| Relmada Therapeutics | 333.67M |
| XOMA Royalty | 331.12M |
| Aldeyra Therapeutics | 330.29M |
| Protara Therapeutics | 319.38M |
| ALX Oncology Holdings | 317.50M |
| Avalo Therapeutics | 312.03M |
| Cellectis | 309.89M |